[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-340674-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-340674-en":131},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","blood-lipid-metabolic-biomarkers-are-emerging-as-significant-prognostic-indicators-for-survival-in-cancer-patients-research-open-access","Blood lipid metabolic biomarkers are emerging as significant prognostic indicators for survival in cancer patients - research open access","","Background Dyslipidemia is a common comorbidity in cancer, yet whether abnormal blood lipid levels reliably predict tumor outcomes remains debated. Methods A systematic literature search evaluated associations between blood lipids (HDL-C, LDL-C, TC, TG, ApoA1, ApoB) and overall survival (OS) or disease-free survival (DFS) using pooled hazard ratios (HRs) and 95% confidence intervals. Results Across 156 studies with 85,173 patients, higher HDL-C, TC, and ApoA1 were linked to improved OS/DFS, while LDL-C, TG, and ApoB showed no significant associations. Conclusion Blood lipids, especially HDL-C, TC, and ApoA1, may serve as accessible prognostic biomarkers to support clinical decision-making.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/blood-lipid-metabolic-biomarkers-are-emerging-as-significant-prognostic-indicators-for-survival-in-cancer-patients-research-open-access/340674/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/blood-lipid-metabolic-biomarkers-are-emerging-as-significant-prognostic-indicators-for-survival-in-cancer-patients-research-open-access/340674.png","ImageObject",300,407,{"name":42,"@type":43},"Genevieve","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-11-03","2026-09-22",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",13,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"Which blood lipid markers were assessed for prognostic value in cancer patients?","Question",{"text":63,"@type":64},"The study evaluated HDL-C, LDL-C, total cholesterol (TC), triglycerides (TG), apolipoprotein A1 (ApoA1), and apolipoprotein B (ApoB).","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"What was the overall evidence linking HDL-C, TC, and ApoA1 to survival outcomes?",{"text":68,"@type":64},"Elevated HDL-C, TC, and ApoA1 were significantly associated with improved overall survival (OS) and disease-free survival (DFS).",{"name":70,"@type":61,"acceptedAnswer":71},"Did LDL-C, TG, and ApoB show significant prognostic relationships?",{"text":72,"@type":64},"No significant relationships were identified between LDL-C, TG, or ApoB levels and OS or DFS in the pooled analyses.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},340674,1790695161,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,111,115,120,123,127],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":107,"doc_module":4,"doc_module_name":25,"category_name":108,"show_sort_weight":109,"slug":110},7,"Healthcare",40,"healthcare",{"id":112,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":113,"slug":114},8,30,"research-report",{"id":116,"doc_module":4,"doc_module_name":25,"category_name":117,"show_sort_weight":118,"slug":119},9,"Religion & Spirituality",20,"religion-spirituality",{"id":118,"doc_module":4,"doc_module_name":25,"category_name":121,"show_sort_weight":118,"slug":122},"World Cup","world-cup",{"id":124,"doc_module":4,"doc_module_name":25,"category_name":125,"show_sort_weight":124,"slug":126},10,"Lifestyle","lifestyle",{"id":128,"doc_module":4,"doc_module_name":25,"category_name":129,"show_sort_weight":97,"slug":130},19,"General","general",{"code":4,"msg":82,"data":132},{"doc_id":79,"user_id":133,"nickname":42,"user_avatar":134,"doc_module":4,"category_id":112,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":135,"file_id":136,"file_url":137,"file_type":138,"file_size":139,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":140,"language":141,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":142,"faqs":143,"seo_title":144,"seo_description":12,"update_tm":145,"read_time":146,"preview_page_count":33,"preview_urls":147},1374391974585,"https://ap-avatar.wpscdn.com/davatar_276721f389ce27ea32af1340a28f341c","Peng et al. BMC Cancer (2024) 24:1549 [https://doi.org/10.1186/s12885-024-13265-8](https://doi.org/10.1186/s12885-024-13265-8)  \nBMC Cancer  \n RESEARCH Open Access  \nBlood lipid metabolic biomarkers are emerging as significant prognostic indicators for survival in cancer patients  \nQiliang Peng1,2,3†, Changli Zhan4†, Yi Shen5†, Yao Xu6†, Bixin Ren7, Zhengyang Feng8, Yong Wang1,2, Yaqun Zhu1,2,3* and Yuntian Shen1,2*  \nAbstract  \nBackground Dyslipidemia is a common comorbidity in patients with cancer, yet the impact of abnormal lipid levelson tumor prognosis remains contentious. This study was conducted to synthesize the current evidence regarding the prognostic utility of blood lipid levels, including high-density lipoprotein cholesterol (HDL-C), low-density lipoprotein cholesterol (LDL-C), total cholesterol (TC), triglycerides (TG), apolipoprotein A1 (ApoA1), and apolipoprotein B (ApoB), in predicting overall survival (OS) and disease-free survival (DFS) in cancer patients.  \nMethods A comprehensive literature search was performed across electronic databases to assess the associations between blood lipid levels and OS or DFS in cancer patients. Pooled hazard ratios (HRs) and 95% confidence intervals (CIs) were calculated to analyze the data. The research protocol was previously submitted to the International Prospective Register of Systematic Reviews (PROSPERO): CRD42023458597 .  \nResults Our study represents the largest and most extensive evaluation of the prognostic significance of blood lipid levels in cancer to date. It includes a meta-analysis of 156 eligible studies involving 85,173 cancer patients. The findings revealed a significant association between elevated levels of HDL-C, TC, and ApoA1 and improved OS and DFSin cancer patients. In contrast, no significant relationships were identified between LDL-C, TG, and ApoB levels and the OS or DFS of cancer patients.  \nConclusion Blood lipids, particularly HDL-C, TC, and ApoA1, emerge as accessible and cost-effective biomarkers that may aid in assessing survival outcomes in cancer patients and potentially inform clinical decision-making. Keywords Blood lipids, Cancer biomarkers, Overall survival, Disease-free survival  \n†Qiliang Peng, Changli Zhan, Yi Shen andYao Xu contributed equally to this work.  \n*Correspondence:  \nYaqun Zhu [szzhuyaqun@sina.com](szzhuyaqun@sina.com)[ ](szzhuyaqun@sina.com)Yuntian Shen [shenyuntian2001@sina.com](shenyuntian2001@sina.com)  \n1 Department of Radiotherapy and Oncology, The Second Affiliated Hospital of Soochow University, Suzhou, China  \n2 Institute of Radiotherapy and Oncology, Soochow University, Suzhou, China  \n3 State Key Laboratory of Radiation Medicine and Protection, Soochow University, Suzhou, China  \n4 Department of Radiotherapy, Luan Hospital of Chinese Medicine Affiliated to Anhui University of Chinese Medicine, Luan, China  \n5 Department of Radiation Oncology, Suzhou Research Center of Medical School, Suzhou Hospital, Affiliated Hospital of Medical School, Nanjing University, Suzhou, China  \n6 Department of Radiology, The Second Affiliated Hospital of Soochow University, Suzhou, China  \n7 Department of Respiratory and Critical Care Medicine, The Second Affiliated Hospital of Soochow University, Suzhou, China  \n8 Department of Oncology, The Second Affiliated Hospital of Soochow University, Suzhou, China  \n© The Author(s) 2024. Open Access This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if you modified the licensed material. You do not have permission under this licence to share adapted material derived from this article or parts of it. The images or other third party material in this article are included in the article’s","cbCaiaqtm7tc3Vra","https://ap.wps.com/l/cbCaiaqtm7tc3Vra","pdf",9914579,38,"English","# Abstract\n## Background\n## Methods\n## Results\n## Conclusion\n# Background\n## Cancer and prognostic biomarkers","[{\"question\":\"Which blood lipid markers were assessed for prognostic value in cancer patients?\",\"answer\":\"The study evaluated HDL-C, LDL-C, total cholesterol (TC), triglycerides (TG), apolipoprotein A1 (ApoA1), and apolipoprotein B (ApoB).\"},{\"question\":\"What was the overall evidence linking HDL-C, TC, and ApoA1 to survival outcomes?\",\"answer\":\"Elevated HDL-C, TC, and ApoA1 were significantly associated with improved overall survival (OS) and disease-free survival (DFS).\"},{\"question\":\"Did LDL-C, TG, and ApoB show significant prognostic relationships?\",\"answer\":\"No significant relationships were identified between LDL-C, TG, or ApoB levels and OS or DFS in the pooled analyses.\"}]","Blood lipid metabolic biomarkers are emerging as significant prognostic indicators for survival in cancer patients - research open access | PDF",1790038105,96,[148,152,156,160],{"page_no":22,"url":149,"width":150,"height":151},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/c2011be78f8639e2212ca08baf36a1b6.webp",983,1305,{"page_no":26,"url":153,"width":154,"height":155},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/0746e8c57f93d2c02556b9afc0d53de8.webp",982,1304,{"page_no":30,"url":157,"width":158,"height":159},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/dd4da8c6941890dea5982ae83e28e6f0.webp",981,1303,{"page_no":33,"url":161,"width":162,"height":163},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/a9b56de501a7cdafcc6792c9d3b4dab8.webp",980,1301]